Opportunistic autoimmunity secondary to immunotherapy and melanoma: Back to ABCDE?

Immune checkpoint inhibitors targeting the cytotoxic T-lymphocyte-associated protein 4 and programmed cell-death protein 1 (PD-1) pathways have transformed the prognosis of patients with advanced-stage melanoma and other selected cancers. The price of this unique efficacy associates with a frequent opportunistic autoimmunity secondary to immunotherapy (OASI), leading to treatment interruption in a large proportion of patients [1]. Therefore, promoting early recognition and adequate management of OASI is worthwhile [2].

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2p0WfP7
via IFTTT